ArticleBMC infectious diseases2025
Daptomycin versus beta-lactam based therapy for the treatment of enterococcal endocarditis and other endovascular infections: a retrospective cohort study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundDaptomycin has a favorable efficacy and safety profile against enterococcal infections, but it is currently a last line treatment for enterococcal infective endocarditis (EIE) due to limited evidence supporting its use.
methodsThis study aimed to investigate clinical outcomes among patients with EIE who received daptomycin versus beta-lactam based therapy. This was a single-center, retrospective cohort study of hospitalized patients with documented EIE and definitive treatment with daptomycin or beta-lactam based therapy between 2011 and 2023. The primary outcome was clinical failure (composite of inpatient infection-related mortality and progression of disease leading to change in therapy). Descriptive statistics assessed baseline demographics, clinical data, and outcomes between patients who received daptomycin versus beta-lactams.
resultsTwenty-six patients receiving daptomycin (median 10 mg/kg/dose) were compared to 102 receiving beta-lactam based therapy (81% ampicillin and ceftriaxone). No significant difference in clinical failure was observed between groups (0% daptomycin vs. 6% beta-lactam; p = 0.35). Individual components of the primary outcome, all-cause mortality, and adverse events leading to therapy discontinuation were similar between groups.
conclusionsOutcomes were similar among patients with EIE treated with daptomycin versus beta-lactams. Larger, prospective studies are needed to confirm this finding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.